嵌合抗原受体 T 细胞疗法及其在血液肿瘤免疫治疗中的应用
网络出版日期: 2017-07-05
基金资助
国家自然科学基金(81570151);上海市教育委员会高峰高原学科建设计划(20152507);上海交通大学SMC- 晨星青年学者奖励计划
Chimeric antigen receptor T-cell immunotherapy and its applications in hematological malignancies immunotherapy
Online published: 2017-07-05
Supported by
National Natural Science Foundation of China, 81570151; Shanghai Municipal Education Commission—Gaofeng Clinical Medicine Grant Support, 20152507; Shanghai Jiao Tong University SMC-Morningstar Young Scholars Program
夏莉 , 王月英 . 嵌合抗原受体 T 细胞疗法及其在血液肿瘤免疫治疗中的应用[J]. 上海交通大学学报(医学版), 2017 , 37(6) : 822 . DOI: 10.3969/j.issn.1674-8115.2017.06.019
Chimeric antigen receptor T-cell (CAR-T) immunotherapy is a new type of immunotherapy, which has been developed rapidly in recent years. By using gene recombination and transfection techniques, CAR-modified effector T cells that specially recognize tumor-associated antigen was produced, which show better properties of targeting, killing activity and durability than conventional T cells. With the development of translational medicine research, CAR-T technology has experienced four generations of optimization and innovation, and presented a promising clinical efficacy in the treatment of various cancers, especially hematological malignancies. However, there are also potential risks with clinical use of this new technology, such as the off-target effect and cytokine storm. In this review, the progress, side effects, coping strategy, and development prospects of CAR-T in hematological malignancies immunotherapy were discussed.
/
〈 |
|
〉 |